Two-year ORBIT II coronary data and long-term economic data presented at SCAI 2015


Cardiovascular Systems (CSI) featured two-year data from its ORBIT II study of the company’s Diamondback 360 coronary orbital atherectomy system, the only US Food and Drug Administration (FDA)-approved atherectomy technology indicated for the treatment of severely calcified lesions, in a late-breaking presentation at the Society for Cardiovascular Angiography and Interventions (SCAI) conference (6–9 May, San Diego, USA).

CSI completed ORBIT II enrolment of 443 patients at 49 US medical centres in November 2012. The pivotal study evaluated the safety and efficacy of the company’s orbital atherectomy technology in treating patients with de novo severely calcified coronary lesions. ORBIT II was the first investigational device exemption study in history to evaluate this problematic subset of patients. In October 2013, CSI received pre-market approval from the FDA to market the Diamondback 360 as a treatment for severely calcified coronary arteries to facilitate stent delivery.

Jeffrey Chambers of Metropolitan Heart and Vascular Institute, Minneapolis, USA, highlighted new data that demonstrated a high freedom from major adverse cardiac events (MACE) rate, including target lesion revascularisation and target vessel revascularisation at two years for this difficult-to-treat patient population.

“ORBIT II two-year data further demonstrates the safety and efficacy of using CSI’s Diamondback 360 orbital atherectomy system to treat severely calcified coronary arteries,” said Chambers. “We have witnessed impressive clinical and economic benefits of using this device in a complex patient population that can be challenging to treat with traditional options. We also know now that using the device prior to stent treatment in severely calcified arteries yields durable, long-term results.”

Chambers presented two-year data showing two-year freedom from:                                                  

  • Major adverse cardiac events (80.6%
  • Myocardial infarction (90.3%)
  • Non Q-wave (91.2%)
  • Q-wave (99.1%)
  • Target vessel revascularisation/target lesion revascularisation (91.9%)
  • Target vessel revascularisation (97.1%)
  • Target lesion revascularisation (93.8%)
  • Cardiac death (95.7%)

Long-term cost effectiveness

Long-term patient outcomes are critical to understanding rates of hospital readmission when evaluating cost savings for the treating institutions and overall healthcare system. The Diamondback 360 has been associated with a shorter length of stay for patients when the device was used to treat severely calcified lesions to facilitate stent placement compared to treating without the Diamondback 360. The lower incidence of readmission and shorter length of stay provide an estimated cost savings of up to US$4,913 per patient to the treating institution at one year following the procedure.

The device offers value with an incremental cost effectiveness ratio of US$11,895 per life year gained, which is below the US$50,000 per quality-adjusted life year threshold considered to be “high value.”